3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Leukemia, Myeloid, Acute
6
Neoplasm Metastasis
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Lung Neoplasms
3
Endometrial Neoplasms
3
Congenital Abnormalities
3
Colonic Neoplasms
3
Breast Neoplasms
3
Sarcoma
2
Oropharyngeal Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Leukemia
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Anus Neoplasms
2
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Stage I Mixed Cell Type Kidney Wilms Tumor
1
Interventions
Rituximab
59
Cyclophosphamide
35
Vincristine
28
Doxorubicin
24
Prednisone
22
Bendamustine Hydrochloride
17
Etoposide
15
Radiotherapy
12
Cytarabine
10
Peripheral Blood Stem Cell Transplantation
8
Filgrastim
8
ibrutinib
7
VAP-cyclo protocol
7
Prednisolone
7
Methotrexate
7
Granulocyte Colony-Stimulating Factor
7
ibritumomab tiuxetan
6
fludarabine
6
Melphalan
6
Gemcitabine
6
pirtobrutinib
5
Mitoxantrone
5
Lenalidomide
5
Carmustine
5
Bleomycin
5
pixantrone
4
Mycophenolic Acid
4
Methylprednisolone
4
Ifosfamide
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Non-Hodgkin
×
Observation
×
Clear all
NCT00877214
2024-08-22
MAINTAIN
University of Giessen
Phase 3
Active not recruiting
1,272 enrolled